0.485
-0.02 (-3.00%)
| Penutupan Terdahulu | 0.500 |
| Buka | 0.482 |
| Jumlah Dagangan | 8,716 |
| Purata Dagangan (3B) | 169,324 |
| Modal Pasaran | 112,457,920 |
| Harga / Buku (P/B) | 208.12 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Operasi (TTM) | -369.31% |
| EPS Cair (TTM) | -0.100 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -39.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 455.33% |
| Nisbah Semasa (MRQ) | 0.340 |
| Aliran Tunai Operasi (OCF TTM) | -13.01 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.74 M |
| Pulangan Atas Aset (ROA TTM) | -238.11% |
| Pulangan Atas Ekuiti (ROE TTM) | -1,277.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | RECCE LTD FPO [RCE] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.75 |
|
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 33.58% |
| % Dimiliki oleh Institusi | 6.53% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |